Company
WuXi Biologics
Headquarters: Wuxi, China
Employees: 9,864
CEO: Dr. Zhisheng Chen
Market Cap
HK$72.27 Billion
HKD as of Jan. 1, 2025
US$9.30 Billion
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
WuXi Biologics (Cayman) Inc., an open-access biologics technology platform company, provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sales of medicals; vaccine CDMO and related business; and material supplier activities. It has strategic partnerships with Almirall, S.A.; Vir Biotechnology, Inc.; Aravive, Inc.; Tubulis GmbH; Arcus Biosciences, Inc.; AC Immune SA; and AB2 Bio Ltd. The company was incorporated in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited.
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | HK$18.37 B |
| EBITDA | HK$5.71 B |
| Gross Profit TTM | HK$7.10 B |
| Profit Margin | 15.38% |
| Operating Margin | 21.22% |
| Quarterly Revenue Growth | 1.00% |
Stocks & Indices
WuXi Biologics has the following listings and related stock indices.
Stock: HKEX: 2269 wb_incandescent
Stock: FSX: 1FW1 wb_incandescent
Stock: OTC: WXIBF wb_incandescent